PCOS in Adults (Pitta-dominant years, ~16-50)

About PCOS in Adults (Pitta-dominant years, ~16-50)

The Rotterdam criteria define adult PCOS as any two of three: ovulatory dysfunction, clinical or biochemical hyperandrogenism, and polycystic ovarian morphology on ultrasound. Roughly ten to thirteen percent of reproductive-age women meet criteria (per the 2023 international evidence-based PCOS guideline), and the phenotype splits along recognizable axes. Phenotype A carries the full picture, B holds anovulation plus hyperandrogenism with normal ovaries, C runs hyperandrogenism plus polycystic morphology with preserved ovulation, and D shows anovulation plus polycystic morphology without androgen excess. Roughly seventy percent show insulin-resistance underneath, and metabolic-syndrome rates run elevated. The chronic-anovulation subset carries endometrial-cancer risk through unopposed estrogen exposure, and long-term cardiovascular and type-2 diabetes risk shifts upward across the reproductive decades. Classical mapping reads PCOS as kapha-medas-rakta-pitta vitiation with agni-mandya at the metabolic root, kleda-prakopa as the insulin-resistance signature, and artava-vaha-srotas derangement at the reproductive expression. Lifestyle is the highest-leverage intervention; a five-to-ten percent weight shift restores ovulation in many adult cases. Ayurveda and modern endocrinology hold no real tension here. Kanchanara-guggulu and metformin work on overlapping ground, inositol bridges both vocabularies, and cyclic progesterone protects the endometrium against chronic anovulatory unopposed-estrogen exposure (with shatavari as ayurvedic adjunct, not a substitute for medical-grade endometrial protection). Treatment splits by goal — contraception, conception, metabolic optimization, or androgen-symptom control — and the active goal sets the move.

Significance

PCOS is the most common endocrine disorder of reproductive age, and the syndrome reaches across three domains at once — metabolic (insulin-resistance, T2D risk, cardiovascular drift), reproductive (anovulation, subfertility, endometrial-cancer risk from unopposed estrogen), and dermatologic (acne, hirsutism, alopecia). Treatment splits by goal: contraception versus conception versus metabolic optimization versus androgen-symptom control, and the right move depends on which axis is being addressed. Lifestyle holds the largest effect size of any single intervention. Ayurvedic kapha-medas clearing, artava-vaha support through basti, seasonal virechana, and herbs like kanchanara-guggulu and shatavari sit alongside modern care — metformin, inositol, letrozole for ovulation induction, spironolactone for hirsutism — without contradiction. Endometrial protection through induced bleeds or cyclic progesterone is the non-negotiable in chronic anovulation.

Connections

PCOS sits on kapha ground with metabolic weight management as the primary lever and pitta heat driving the hyperandrogenism layer. Shatavari anchors artava-vaha support, lodhra holds uterine tone, and fenugreek addresses insulin-resistance at the metabolic layer. Basti is the classical artava-vaha intervention, with ashoka, manjistha, and kanchanara-guggulu alongside as the skin-clearing and uterine-toning frame the syndrome asks for across the reproductive decades.

Further Reading

• Charaka Samhita Chikitsa Sthana ch 30 (Yonivyapad Chikitsa). Sushruta Samhita Sharira Sthana ch 2 on shukra-shonita-shuddhi. Ashtanga Hridayam Uttara Sthana ch 34 Guhyaroga Pratishedha. Classical aartavadushti and aartavakshaya. Modern: Rotterdam 2003 + 2018 update; international evidence-based PCOS guideline (Teede 2018, 2023, Human Reproduction); inositol meta-analyses (Unfer).